Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Clinical trial NCT04204928 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT04204928
- Sponsor
- Blueprint Medicines Corporation
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.